Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-13
2011-12-20
Myers, Carla (Department: 1634)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S789000, C435S006100, C435S006110, C435S006170, C435S007100, C536S023500, C536S024310, C530S350000
Reexamination Certificate
active
08080578
ABSTRACT:
The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).
REFERENCES:
patent: 4234595 (1980-11-01), Kreighbaum et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5002867 (1991-03-01), Macevicz
patent: 5130238 (1992-07-01), Malek et al.
patent: 5169766 (1992-12-01), Schuster et al.
patent: 5202231 (1993-04-01), Drmanac et al.
patent: 5302509 (1994-04-01), Cheeseman
patent: 5595880 (1997-01-01), Weinshank et al.
patent: 5648482 (1997-07-01), Meyer
patent: 5679524 (1997-10-01), Nikiforov et al.
patent: 5766851 (1998-06-01), Shuldiner et al.
patent: 5846710 (1998-12-01), Bajaj
patent: 5856092 (1999-01-01), Dale et al.
patent: 5888819 (1999-03-01), Goelet et al.
patent: 5981174 (1999-11-01), Wolf et al.
patent: 5998458 (1999-12-01), Bristow
patent: 6004744 (1999-12-01), Goelet et al.
patent: 6013431 (2000-01-01), Söderlund et al.
patent: 6156503 (2000-12-01), Drazen et al.
patent: 6221851 (2001-04-01), Feldman
patent: 6316188 (2001-11-01), Yan et al.
patent: 6365618 (2002-04-01), Swartz
patent: 6498009 (2002-12-01), Liggett
patent: 6566101 (2003-05-01), Shuber et al.
patent: 6586183 (2003-07-01), Drysdale et al.
patent: 6784177 (2004-08-01), Cohn et al.
patent: 6797472 (2004-09-01), Liggett
patent: 6821724 (2004-11-01), Mittman et al.
patent: 6861217 (2005-03-01), Liggett
patent: 7041810 (2006-05-01), Small et al.
patent: 7195873 (2007-03-01), Fligheddu et al.
patent: 7211386 (2007-05-01), Small et al.
patent: 7229756 (2007-06-01), Small et al.
patent: 7449292 (2008-11-01), Liggett et al.
patent: 7572603 (2009-08-01), Small et al.
patent: 7642052 (2010-01-01), Small et al.
patent: 7678824 (2010-03-01), Liggett et al.
patent: 2001/0016338 (2001-08-01), Snapir et al.
patent: 2001/0051712 (2001-12-01), Drysdale et al.
patent: 2002/0187491 (2002-12-01), Johnson
patent: 2003/0039979 (2003-02-01), Liggett et al.
patent: 2003/0091998 (2003-05-01), Drysdale et al.
patent: 2003/0113725 (2003-06-01), Small et al.
patent: 2003/0124636 (2003-07-01), Leyland-Jones
patent: 2003/0143608 (2003-07-01), Filigheddu et al.
patent: 2003/0233118 (2003-12-01), Hui
patent: 2004/0023967 (2004-02-01), Cohn et al.
patent: 2004/0033524 (2004-02-01), Johnson
patent: 2004/0106954 (2004-06-01), Whitehurst et al.
patent: 2004/0192625 (2004-09-01), Liggett
patent: 2006/0073508 (2006-04-01), Small et al.
patent: 2008/0269346 (2008-10-01), Johnson et al.
patent: 2009/0092964 (2009-04-01), Liggett
patent: 2009/0228995 (2009-09-01), Liggett et al.
patent: 0329822 (1994-06-01), None
patent: 0874048 (1998-10-01), None
patent: 06-121686 (1994-05-01), None
patent: WO 88/10315 (1988-12-01), None
patent: WO 89/06700 (1989-07-01), None
patent: WO 89/10414 (1989-11-01), None
patent: WO 90/01069 (1990-02-01), None
patent: WO 90/09455 (1990-08-01), None
patent: WO 91/02087 (1991-02-01), None
patent: WO 92/15712 (1992-09-01), None
patent: WO 94/03630 (1994-02-01), None
patent: WO 95/17676 (1995-06-01), None
patent: WO 95/33048 (1995-12-01), None
patent: WO 97/11698 (1997-04-01), None
patent: WO 99/13721 (1999-03-01), None
patent: WO 99/19512 (1999-04-01), None
patent: WO 00/20450 (2000-04-01), None
patent: WO 00/22166 (2000-04-01), None
patent: WO 00/31307 (2000-06-01), None
patent: WO 01/11039 (2001-02-01), None
patent: WO 01/29082 (2001-04-01), None
patent: WO 01/79561 (2001-10-01), None
patent: WO 02/09760 (2002-02-01), None
patent: WO 02/071070 (2002-09-01), None
patent: WO 03/057920 (2003-07-01), None
patent: WO 03/088978 (2003-10-01), None
patent: WO 2004/011018 (2004-02-01), None
patent: WO 2004/023101 (2004-03-01), None
patent: WO 2005/025409 (2005-03-01), None
Borjesson et al., “A novel polymorphism in the gene coding for the beta 1-adrenergic receptor associated with survival in patients with heart failure,”Eur Heart J., 21:1853-1858, 2000.
Bouzamondo et al., “Beta-blocker treatment in heart failure,”Fundamental&Clinical Pharmacology, 15:95-109, 2001.
Bristow et al. “Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?”J Card Fail. 9:444-53, 2003.
Bristow et al., “Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial,”Circulation. 110:1437-42, 2004.
Bristow et al., “The role of third-generation beta-blocking agents in chronic heart failure,”Clinical Cardiology, 21(Suppl I):I-3-I-13, 1998.
Bristow et al., “α2c-adrenergic receptor 322-325 Del polymorphism enhance the sympatholytic effect of bucindolol, and adversely affected clinical outcomes in the BEST trial,”Circulation112:II-351, 2005.
Bristow, “Antiadrenergic therapy of chronic heart failure: surprises and new opportunities,”Circulation, 107:1100-2, 2003.
Bristow, “Beta-adrenergic receptor blockade in chronic heart failure,”Circulation, 101:558-69, 2000.
Brodde and Stein, “The gly389arg β1—adrenergic receptor polymorphism: a predictor of response to β-blocker treatment?”Clinical Pharmacology and Therapeutics, 74:299-302, 2003.
Domanski et al., “A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS,”Journal of Cardiac Failure, 9(5):354-63, 2003.
Domanski et al., “The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial,”J Am Coll Cardiol. 42:914-22, 2003.
Eichhorn and Bristow “Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure,”Am J Cardiol, 79:794-8, 1997.
Eichhorn et al., “A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure,”N Engl J Med, 344:1659-67, 2001.
Fagerberg et al., “Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF)”The Lancet, 353:2001-2007, 1999.
Filigheddu et al., “Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade,”The Pharmacogenomics Journal, 4:154-160, 2004.
Flather et al., “FASTTRACK randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS),”The European Heart Journal, 26:215-225, 2005.
Forleo et al., “Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy,”Am J Med., 117:451-8, 2004.
Gene Card for ADRA2C/α2c-AR available via url: <genecards.org/cgi-bin/carddisp.pl?gene=Adra2c>, Feb. 6, 2008.
Gene Card for ADRBI/β1-AR available via url: <genecards.org/cgi-bin/carddisp.pl?gene=ADRBI>, Feb. 6, 2008.
Goldstein et al., “Metoprolol controlled release/extended release in patients with severe heart failure,”J of Am College of Cardiology, 38:932-8, 2001.
Goldstein, “Beta blocker therapy in African American patients with heart failure,”Heart Fail Rev., 9:161-7, 2004.
Hein et al., “Two functionally distinct a2-adrenergic receptors regulate sympathetic neurotransmission,”Nature, 402:181-184, 1999.
Humma and Terra, “Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management,”Am J Health-Syst Pharm, 59:1241-1252, 2002.
Iwai et al., “Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction,”Am. Heart J., 146:106-109, 2003.
Johnson and Terra., “β-adrenergic receptor po
Bristow Michael
Liggett Stephen B.
Fulbright & Jaworski L.L.P.
Myers Carla
The Regents of the University of Colorado, a body corporate
LandOfFree
Methods for treatment with bucindolol based on genetic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment with bucindolol based on genetic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment with bucindolol based on genetic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4314254